AzTrials
AzTrials

Asthma in ChildrenNCT05139485

Evaluation of a Remote Asthma Monitoring Program to Improve Health Outcomes in Pediatric Asthma

An observational study of Asthma in Children, run by Weill Medical College of Cornell University at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The primary objective of this pilot study to is to determine the overall impact of a clinical program of remote medication monitoring administered by St. Mary's Homecare on disease control in pediatric asthma patients. Read more about this study

Who is it for?
Ages 3 to 21 years
Conditions the study is for
Asthma in Children
How many people
12 participants
Where
1 siteUnited States
Study dates
10 Jun 2021to 23 Mar 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Subjects between the ages of 3 and 21 years who have a diagnosis of persistent asthma (mild, moderate or severe) who have poorly controlled symptoms

Who may be able to join

  • Age 3- 21 years
  • Diagnosis of persistent asthma (mild, moderate, severe) previously diagnosed by a physician
  • Diagnosis of poorly controlled asthma or and asthma control test (ACT) score of <19

Who cannot join

  • Patients who have severe cognitive delay, significant mental illness which impairs daily functioning or are non-verbal will be excluded as they are less likely to benefit from the educational techniques administered
  • Primary language other than English or Spanish

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Weill Cornell Medicine

    New York, New York, 10021

Other trials in United States

About this study

The primary objective of this pilot study to is to determine the overall impact of a clinical program of remote medication monitoring administered by St. Mary's Homecare on disease control in pediatric asthma patients. The central hypothesis is that a short-term program of remote asthma medication monitoring paired with home visits and asthma education will be associated with a sustained improvement in asthma symptom control in children over time.

Read the detailed description

This is a pilot, prospective observational cohort study of 20 children with poorly controlled persistent asthma over 12 months exploring response to an intensive asthma monitoring and education program. The program consists of the following administered over a 6-month period: 1) A remote medication monitoring system (Propeller devices and monitoring administered by St. Mary's Healthcare) and 2) home visits by St. Mary's asthma nurses. The Propeller devices are electronic inhaler sensors which monitor the use of metered dose inhalers (as well as other medication delivery devices) and captures the date and time of use. This is an FDA approved device aimed at promoting asthma self-management in a cost-effective manner. The sensor stores and transmits information via Bluetooth to a paired wireless data transmitter, which sends the data to a secured server accessible by St. Mary's Healthcare.

The study will consist of two phases described below. Phase 1 (Months 1-6): Subjects are enrolled in the St. Mary's Healthcare home visiting and remote medication monitoring program through referral by the physicians/nurse practitioners providing asthma care and the Weill Cornell Pediatric Asthma Program. They will then undergo an initial home visit by a St. Mary's asthma program nurse, where they are equipped with Propeller devices for their controller medication (as prescribed by their physician) and rescue medication (albuterol), and are connected to St. Mary's remote monitoring system. Remote monitoring, home visits and in-person/video visit clinical assessment with asthma education will be provided during this time (see below). The St. Mary's remote monitoring system and telehealth nurse collects medication administration data obtained through the Propeller monitoring system in real-time, which is made available clinically to the subjects' medical providers on a monthly basis for review, or if there is substantial deviation from prescribed medication administration or increased use of rescue medication necessitating an intervention by St. Mary's telehealth nurses.

Additionally, the following outcomes data will be collected on a monthly basis via telephone or office/video visit by the study team to assess overall asthma control and health care use: Number of emergency room visits or hospitalizations for asthma in the last month, number of urgent care or primary care visits for asthma symptoms, number of albuterol prescriptions renewed, number of oral steroid prescriptions filled, number of missed school days, and an ACT score to assess control. Pulmonary function testing (PFT) will be performed at the time of enrollment.

Phase 2 (Months 7-12): Subjects will have completed remote asthma medication monitoring by the St. Mary's Program, and are observed for an additional 6 months by the study team to determine the response to the administered program. Subjects will have outcomes data (as described in Phase 1) collected via telephone or video visit; a minimum of 2 provider office or video visits will occur during this phase. PFTs will be performed at least once during this period.

Remote monitoring: Remote devices collect prospective data regarding use of controller medication as prescribed and any doses of rescue medication administered. If a patient is using their rescue inhaler above or using their controller inhaler less than prescribed, a St. Mary's Telehealth Nurse will receive an alert in real time. The Telehealth Nurse will contact the patient or caregiver to assess the situation and intervene, either by providing reminders or assessing for changes in clinical status. The Telehealth Nurse will initiate communication with their medical provider or emergency services as appropriate.

Home visits: Subjects enrolled in this program will be provided with up to 6 asthma nursing visits over the 12month study period as standard practice of St. Mary's home visitation program and based on the individual needs of the subject. A minimum of 2 nursing visits will be administered during phase 1 for clinical monitoring and asthma education/asthma management reinforcement.

Provider visits: Patients will have a physician office or video visit with NYPH-WCM providers scheduled during Month 2 and Month 5 of Phase 1 for standard clinical follow up, and to review their medication usage and provide directed feedback. This will be bundled with a dedicated asthma education session with WCM-Pediatric Asthma Program asthma educators to review/reinforce medication administration techniques and provide tailored asthma education for the development of asthma self-management skills. There will be a minimum of 2 scheduled Provider visits during Phase 2.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in asthma control test (ACT) scores

    This outcome will compare ACT scores at the time of enrollment, to month 6 and month 12 scores

    Measured: Baseline (enrollment), Month 6 and Month12

Secondary outcomes (7)
  1. Change in percent of Controller Medication administered

    The percent of prescribed medication doses administered per month with comparison of mean percentage at month 3, month 6 and month 12

    Measured: 3 months, 6 months and 12months

  2. Change in number of Rescue Medication doses administered

    The number of rescue medication doses administered per month, with comparison of mean number of doses at month 3, month 6 and month 12

    Measured: 3 months, 6 months and 12months

  3. Change in health-care use: Number of physician visits

    This secondary outcome will compare the number of physician visits due to asthma in the 12 month period pre-enrollment, to the number of physician visits due to asthma during the study period in month 12 (at completion of study).

    Measured: Enrollment, Month 12

  4. Change in health-care use: Number of Emergency Department (ED) visits

    This secondary outcome will compare the number of ED visits due to asthma in the 12 month period pre-enrollment, to the number of ED visits due to asthma during the study period in month 12 (at completion of study).

    Measured: Enrollment, Month 12

  5. Change in health-care use: Number of Hospitalizations

    This secondary outcome will compare the number of hospitalizations due to asthma in the 12 month period pre-enrollment, to the number of hospitalizations due to asthma during the study period in month 12 (at completion of study).

    Measured: Enrollment, Month 12

  6. Change in health-care use: Number of oral steroid courses

    This secondary outcome will compare the number of oral steroid courses prescribed due to an asthma exacerbation in the 12 month period pre-enrollment, to the number of oral steroid courses prescribed over the study period at month 12.

    Measured: Enrollment, Month 12

  7. Change in number of missed school days

    Number of missed school days due to asthma in the 12-month period prior to enrollment compared to number of school days missed over the study period at month 12.

    Measured: Enrollment, month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2021
  2. Study start10 Jun 2021
  3. Primary completion23 Mar 2023
  4. Study completion23 Mar 2023

Why it stopped: Staffing issues with partner site.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05139485
Sponsor's protocol ID
20-06022311
Status last verified
Aug 2025
First submitted
18 Nov 2021
Last updated
17 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Asthma in Children, run by Weill Medical College of Cornell University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Staffing issues with partner site.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in asthma control test (ACT) scores (time frame: Baseline (enrollment), Month 6 and Month12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in